No Data
Fate Therapeutics | 10-Q: Quarterly report
Earnings Flash (FATE) FATE THERAPEUTICS Reports Q1 Revenue $1.9M
04:07 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (FATE) FATE THERAPEUTICS Reports Q1 Revenue $1.9M
Fate Therapeutics 1Q Loss/Shr 47c >FATE
Fate Therapeutics 1Q Loss/Shr 47c >FATE
Press Release: Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical
Fate Therapeutics Advances in Autoimmune and Cancer Therapies
Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy
Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy